Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.

ABSTRACT:

Purpose

Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men receiving androgen deprivation therapy during a 2-year period.

Materials and methods

In this double-blind, placebo controlled phase III study 646 men receiving androgen deprivation therapy for prostate cancer were assigned to toremifene (80 mg by mouth daily) and 638 were assigned to placebo. Subjects were followed for 2 years. The primary study end point was new vertebral fractures. Secondary end points included fragility fractures, bone mineral density and lipid changes.

Results

The 2-year incidence of new vertebral fractures was 4.9% in the placebo group vs 2.5

SUBMITTER: Smith MR 

PROVIDER: S-EPMC3047407 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature